MARKET

RLFTY

RLFTY

Relief Therapeut
OTCMQB
3.700
NaN%
Closed 09:30 12/04 EST
OPEN
--
PREV CLOSE
3.700
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
18.00
52 WEEK LOW
2.640
MARKET CAP
46.53M
P/E (TTM)
-2.1620
1D
5D
1M
3M
1Y
5Y
1D
Relief Therapeutics and NeuroX Reveal Joint Presentation and Financial Outlook Ahead of Anticipated Merger
Reuters · 11/25 06:02
Relief Therapeutics Shareholders Approve Merger with NeuroX
Reuters · 11/14 17:22
Relief Therapeutics Reports Positive Bioequivalence Results for RLF-OD032 in PKU Study
Reuters · 10/29 06:00
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
Barchart · 10/28 21:20
Relief Therapeutics Calls Shareholder Vote on NeuroX Group Merger
Reuters · 10/24 05:00
Relief Therapeutics and NeuroX successor to MindMaze sign definitive agreement for business combination
Reuters · 10/08 05:00
Weekly Report: what happened at RLFTY last week (0908-0912)?
Weekly Report · 09/15 11:14
Weekly Report: what happened at RLFTY last week (0901-0905)?
Weekly Report · 09/08 11:17
More
About RLFTY
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.

Webull offers RELIEF THERAPEUTICS Holding SA stock information, including OTCMQB: RLFTY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLFTY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLFTY stock methods without spending real money on the virtual paper trading platform.